View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
November 24, 2009

Simulations Plus Unveils New Version Of GastroPlus

Simultaneously working on Version 7.0 that is expected to be released early next year

By CBR Staff Writer

Simulations Plus has released GastroPlus Version 6.1, the latest version of its software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.

Viera Lukacova, team leader of Simulation Technologies at Simulations Plus’ said: “This new version of GastroPlus incorporates both new types of analysis as well as numerous user convenience features suggested by our worldwide user community. The simulation capability has been expanded to include dosing to the oral cavity via lingual (top of the tongue), sublingual (under the tongue), and buccal (inside the cheek) routes of administration.

“As a result of suggestions from our users, we’ve also added a long list of convenience features that help both new and experienced users to avoid common mistakes, to provide flexible units for various input data, and to extend the output options in both graphics and text formats.

Additionally, we’ve added a major improvement that affects certain low-solubility drugs by incorporating the distribution of bile salts in the intestinal tract for both fasted and fed conditions, and we’ve added the ability to estimate the improved solubility from nanoparticle formulations. Both of these solubility-related improvements provide dramatically better prediction of the dissolution rate and subsequent absorption of drugs that fall into these categories.”

Content from our partners
AI is transforming efficiencies and unlocking value for distributors
Collaboration along the entire F&B supply chain can optimise and enhance business
Inside ransomware's hidden costs

The company said that Simulating these routes of administration extends the capabilities of GastroPlus into new areas with the potential of new customers, in both drug and drug delivery companies.

Simulations Plus is working on Version 7.0, which is expected to be released early next year. That version will include a comprehensive drug-drug interaction capability as well as the ocular and nasal/pulmonary administration routes that the company has been developing under its funded collaborations with major pharmaceutical companies.

Walt Woltosz, chairman and CEO of Simulations Plus, said: “Most people are aware that nitroglycerin pills are placed under the tongue where they dissolve and are absorbed. There are a number of rapid-dissolving formulations and some lingual sprays on the market that are absorbed at least partially from the oral cavity, as well as some adhesive buccal patches that stick to the inside of the cheek and release drug slowly.

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.